



**Pfizer Australia**  
38 - 42 Wharf Road  
West Ryde NSW 2114

3 March 2017

Committee Secretary  
Senate Standing Committees on Community Affairs  
PO Box 6100  
Parliament House  
Canberra ACT 2600

*via email: [community.affairs.sen@aph.gov.au](mailto:community.affairs.sen@aph.gov.au)*

Dear Committee Secretary,

**RE: INQUIRY INTO THE THERAPEUTIC GOODS AMENDMENT (2016 MEASURES NO. 1) BILL 2016**

Thank you for providing Pfizer Australia with the opportunity to comment on the Senate Standing Committee on Community Affairs' inquiry into the *Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016*.

Pfizer Australia is one of Australia's leading providers of prescription medicines and consumer health products. We manufacture medicines and vaccines that millions of Australians use every day to live longer, healthier and more productive lives. We are proud of the active role we play in Australia's health system and the wider contribution we make as an innovator, employer and manufacturer.

Pfizer Australia is a member of Medicines Australia, the peak body representing innovative pharmaceutical companies in Australia. We support Medicines Australia's submission to this inquiry and encourage the Committee to carefully consider its key messages:

- The Bill supports more timely access to medicines for Australian patients
- The Bill does not dilute or reduce the Therapeutic Goods Administration's statutory focus on medicine safety, efficacy and quality
- The Bill will align the Therapeutic Goods Administration with the world's best regulatory systems
- The Bill reflects the extensive consultation undertaken during and following the independent Medicines and Medical Devices Review over the past two years
- Stakeholders will be able to review the details of subsequent regulations.

We urge the Committee to recommend passage of the *Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016* by the Senate.

Yours sincerely,

**Brian Hewitt**  
Head of Regulatory Affairs ANZ